Upregulation of miR‑520b promotes ovarian cancer growth

Guan,Rui; Cai,Shengyun; Sun,Mingjuan; Xu,Mingjuan

doi:10.3892/ol.2017.6552

Upregulation of miR‑520b promotes ovarian cancer growth

Authors:
- Rui Guan
- Shengyun Cai
- Mingjuan Sun
- Mingjuan Xu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: July 8, 2017 https://doi.org/10.3892/ol.2017.6552
Pages: 3155-3161

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the most common gynecological malignant cancer in female genitalia. Dysregulation or dysfunction of microRNAs (miRs) contribute to cancer development. The role of miR‑520b in ovarian cancer remains unclear. The present study investigated the role of miR‑520b in ovarian cancer and determined that the expression levels of miR‑520b in ovarian cancer tissues and cell lines were upregulated. By contrast, reverse transcription-quantitative polymerase chain reaction and immunohistochemistry revealed that the mRNA and protein expression levels of ring finger protein 216 (RNF216) were downregulated in ovarian cancer, indicating that there was a negative correlation between miR‑520b and RNF216. In miR-520b-knockdown cells, downregulation of miR‑520b reduced cell proliferation, while upregulation of miR‑520b promoted cell proliferation. In addition, RNF216 was predicted by TargetScanHuman and was observed to be targeted by miR‑520b. In conclusion, the present data indicated that high expression of miR‑520b in ovarian cancer promoted cell growth via RNF216.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Zhao YN, Chen GS and Hong SJ: Circulating MicroRNAs in gynecological malignancies: From detection to prediction. Exp Hematol Oncol. 3:142014. View Article : Google Scholar : PubMed/NCBI
3	Rooth C: Ovarian cancer: Risk factors, treatment and management. Br J Nurs. 22:S23–S30. 2013. View Article : Google Scholar : PubMed/NCBI
4	Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL and Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 20:1248–1259. 2002. View Article : Google Scholar : PubMed/NCBI
5	Winter-Roach BA, Kitchener HC and Lawrie TA: Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 3:CD0047062012.
6	Winter-Roach BA, Kitchener HC and Dickinson HO: Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev: CD004706. 2009. View Article : Google Scholar
7	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
8	Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
9	Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
10	Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
11	Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell. 148:1172–1187. 2012. View Article : Google Scholar : PubMed/NCBI
12	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
13	Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res. 67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
14	Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM and Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 112:55–59. 2009. View Article : Google Scholar : PubMed/NCBI
15	Chung YW, Bae HS, Song JY, Lee JK, Lee NW, Kim T and Lee KW: Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients. Int J Gynecol Cancer. 23:673–679. 2013. View Article : Google Scholar : PubMed/NCBI
16	Shapira I, Oswald M, Lovecchio J, Khalili H, Menzin A, Whyte J, Dos Santos L, Liang S, Bhuiya T, Keogh M, et al: Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer. 110:976–983. 2014. View Article : Google Scholar : PubMed/NCBI
17	Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, et al: Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res. 19:1213–1224. 2013. View Article : Google Scholar : PubMed/NCBI
18	Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W and Chen K: Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 8:e778532013. View Article : Google Scholar : PubMed/NCBI
19	Kan CW, Hahn MA, Gard GB, Maidens J, Huh JY, Marsh DJ and Howell VM: Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer. 12:6272012. View Article : Google Scholar : PubMed/NCBI
20	Hu N, Zhang J, Cui W, Kong G, Zhang S, Yue L, Bai X, Zhang Z, Zhang W, Zhang X and Ye L: miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8. J Biol Chem. 286:13714–13722. 2011. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	van Meerloo J, Kaspers GJ and Cloos J: Cell sensitivity assays: The MTT assay. Methods Mol Biol. 731:237–245. 2011. View Article : Google Scholar : PubMed/NCBI
23	Han ZB, Yang Z, Chi Y, Zhang L, Wang Y, Ji Y, Wang J, Zhao H and Han ZC: MicroRNA-124 suppresses breast cancer cell growth and motility by targeting CD151. Cell Physiol Biochem. 31:823–832. 2013. View Article : Google Scholar : PubMed/NCBI
24	Song B, Zhang C, Li G, Jin G and Liu C: MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015. View Article : Google Scholar : PubMed/NCBI
25	Wu N, Zhang C, Bai C, Han YP and Li Q: MiR-4782-3p inhibited non-small cell lung cancer growth via USP14. Cell Physiol Biochem. 33:457–467. 2014. View Article : Google Scholar : PubMed/NCBI
26	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
27	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
28	Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. Mol Cell. 27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
29	Garcia DM, Baek D, Shin C, Bell GW, Grimson A and Bartel DP: Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
30	Grentzmann G, Ingram JA, Kelly PJ, Gesteland RF and Atkins JF: A dual-luciferase reporter system for studying recoding signals. RNA. 4:479–486. 1998.PubMed/NCBI
31	Xu XS, Wang L, Abrams J and Wang G: Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. J Hematol Oncol. 4:172011. View Article : Google Scholar : PubMed/NCBI
32	Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X and Song Y: Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One. 7:e350652012. View Article : Google Scholar : PubMed/NCBI
33	Zhang W, Kong G, Zhang J, Wang T, Ye L and Zhang X: MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1. PLoS One. 7:e314502012. View Article : Google Scholar : PubMed/NCBI